169 related articles for article (PubMed ID: 27918226)
1. Canagliflozin use in Type I diabetes mellitus.
Guthrie R
Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
[TBL] [Abstract][Full Text] [Related]
2. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Danford C; Chan P; Magill SB
WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
[TBL] [Abstract][Full Text] [Related]
3. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
Dhatariya K
Diabetes Care; 2016 Jan; 39(1):e18. PubMed ID: 26696665
[No Abstract] [Full Text] [Related]
4. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
Ou HY; Karnchanasorn R; Chuang LM; Chiu KC
Diabetes Care; 2015 Nov; 38(11):e198. PubMed ID: 26494820
[No Abstract] [Full Text] [Related]
5. Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
Erondu N; Desai M; Ways K; Meininger G
Diabetes Care; 2016 Jan; 39(1):e19. PubMed ID: 26696666
[No Abstract] [Full Text] [Related]
6. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Adachi J; Inaba Y; Maki C
Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
8. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
Novik A V; García B C; Oliva I D
Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
10. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
Clement M; Senior P
Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
[No Abstract] [Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
12. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
Ramirez Tello EM; Orellana-Barrios MA; Nugent K
Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
[No Abstract] [Full Text] [Related]
13. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes.
Harati H; Sharma V; Motazedi A
J Diabetes; 2016 Jan; 8(1):165. PubMed ID: 26211700
[No Abstract] [Full Text] [Related]
15. RE: DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Bell DSH
Endocr Pract; 2018 Jan; 24(1):126. PubMed ID: 29368970
[No Abstract] [Full Text] [Related]
16. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
[TBL] [Abstract][Full Text] [Related]
17. In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
Sfeir JG; Montori VM
Ann Intern Med; 2016 Jul; 165(2):JC2. PubMed ID: 27429314
[No Abstract] [Full Text] [Related]
18. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
[TBL] [Abstract][Full Text] [Related]
19. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
Rendell MS
Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
Henry RR; Thakkar P; Tong C; Polidori D; Alba M
Diabetes Care; 2015 Dec; 38(12):2258-65. PubMed ID: 26486192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
